Rochelle Walensky, Centers for Disease Control and Prevention Director (CDC)
In early December, Dr. Katy Stephenson was watching TV with her family and scrolling through Twitter when she saw a tweet that made her shout.
“I said ‘Oh, my God!’” she recalled. “Super loud. My kids jumped up. My husband looked over. He said, ‘What’s wrong, what’s wrong, is everything OK?’ I was like, ‘No, no, it’s the opposite. It’s amazing. This is amazing!’”
Dr. Rochelle Walensky had just been tapped to lead the Centers for Disease Control and Prevention.
Stephenson is an infectious diseases specialist and vaccine scientist at Beth Israel Deaconess Medical Center in Boston. So the news had special meaning for her and the many jubilant colleagues tweeting their joy. They’d been helping one another through the brutal pandemic year, she said, while feeling they had little to no help from the federal government.
“It was so baffling,” she said. “It wasn’t even just that we didn’t know what the government was doing. It was that sometimes it felt like sabotage. Like the federal government was actively trying to mess things up.”
But through it all, as the long months became a year, Walensky had been out front, Stephenson said, sticking to the science and telling the truth.
When Walensky stepped up to lead the CDC, she promised to keep telling the truth — even when it’s bad news. She told a JAMA Network podcast last month that she’ll welcome straight talk from the scientists at the CDC as well.
“They have been diminished,” she said. “I think they’ve been muzzled — that science hasn’t been heard. This top-tier agency, world-renowned, hasn’t really been appreciated over the last four years and really markedly over the last year, so I have to fix that.”
Walensky, 51, has long been a doctor on a mission — first, to fight AIDS around the world, and now, to shore up the CDC and get the United States through the pandemic. Beyond unmuzzling her agency’s staff, she vows to tackle many other challenges, pushing particularly hard on vaccine distribution and rebuilding the public health system.
Walensky’s family has a tradition of service, including a grandfather who served in World War II and rose to be a brigadier general. And she likens the call she got from the Biden administration to a hospital alarm that goes off when a patient is in cardiac arrest.
“I got called during a code,” she told JAMA. “And when you get called during a code, your job is to be there to help.”
At Massachusetts General Hospital, where Walensky was the chief of infectious diseases, some of her many admirers now have T-shirts that read “Answer the Code” with her initials, RPW, beneath.
The shirts are part of an outpouring of affection in Boston biomedical circles and far beyond that greeted Walensky’s appointment — including a flood of floral bouquets that her husband and three sons helped accept after word of her new job got out.
“At one point, one of my sons said, ‘You know, Dad, we should just open a florist shop at this point,” said Dr. Loren Walensky, the CDC director’s husband.
He studies and treats children’s blood cancers at Boston Children’s Hospital and the Dana-Farber Cancer Institute. And now he could be called the “first gentleman” of the CDC.
He calls Rochelle his “Wonder Woman” and still remembers when he first saw her 30 years ago, in the cafeteria of the Johns Hopkins University School of Medicine, where they were both students.
“She stood out,” he said. “And one of the reasons why she stood out is because she stands tall. Rochelle is 6 feet tall.”
She also had extraordinary energy and discipline, even then, he remembered: “Most of us would roll out of bed and stumble into the lecture hall as our first activity of the day and, for Rochelle, she was already up and running and bright-eyed and bushy-tailed for hours before any of us ever saw the light of day.”
After medical school, Rochelle Walensky trained in a hospital medical unit so tough it was compared to the Marines. It was the mid-’90s, and the AIDS epidemic was raging. She saw many people die. And then, a few years later, she saw the advent of HIV treatments that could save patients — if those patients could get access to testing and care.
Loren Walensky recalls coming home one day to find her sitting at the kitchen table working on extremely complex math. She was starting to broaden her focus from patient care to bigger-picture questions about the increased equity in health care that more funding and optimal treatment choices could bring.
“And it was like a switch went off,” he said, “and she just had this natural gift for this style of testing — whether if you did X, would Y happen, and if you did X with a little more money, then how would that affect Y? And all of these if-thens.”
She started doing more research, including studies of ways to get more patients tested and treated for AIDS, even in the poorest countries. One of her most prominent papers calculated that HIV drugs had given American patients at least 3 million more years of life.
She worked with Dr. Ken Freedberg, a leading expert on how money is best spent in medicine.
“You can’t do everything,” Freedberg said, “and even if you could, you can’t do everything at once. So what Rochelle is particularly good at is understanding data about treatments and public health and costs, and putting those three sets of data together to understand, ‘Well, what do we do? And what do we do now?’”
So, if Walensky had a Wonder Woman superpower, it was using data to inform decisions and save lives. That analytic skill has come in handy over the past year, as she has helped lead the pandemic response for her Boston hospital and for the state of Massachusetts.
She has weighed in often — and publicly — about coronavirus policy and medicine, speaking to journalists with a seemingly natural candor that has contrasted with the stiffer style of some federal officials. In April, when a huge surge of covid cases hit, she acknowledged the pain.
“We are experiencing incredibly sad days,” she said in a spring interview. “But we sort of face every day with the hope and the vision that what we will be faced with, we can tackle.”
And in November, she offered a sobering reality check from the front lines about current covid medical treatments: “When I think about the armamentarium of true drugs that we have that benefit people with this disease, it’s pretty sparse,” she said.
Walensky published research on key pandemic topics, such as college testing and antibody treatments. And she weighed in often publicly — on Twitter, in newspapers and on radio and TV. Asked on CNN whether the President Joe Biden’s plan to get 100 million Americans vaccinated in 100 days could restore a sense of normalcy, she responded with characteristic bluntness — a quality that could cause trouble in these polarized times.
“I told you I’d tell you the truth,” she said. “I don’t think we’re going to feel it then. I think we’re still going to have, after we vaccinate 100 million Americans, we’re going to have 200 million more that we’re going to need to vaccinate.”
Walensky is facing a historic challenge and leading an agency for which she’s never worked.
Still, Boston colleagues said they have no doubt she’ll succeed in making the transition from leading an infectious diseases division of 300 staffers to a public health agency of about 13,000.
“I would lie down in traffic for her,” said Elizabeth Barks, the infectious diseases division’s administrative director at Mass General. “And I think our entire division would lie down in traffic for her.”
Leading and rebuilding the CDC in the midst of a pandemic will be difficult. But Barks and others who know Walensky well said she’s clear-eyed and ready to dig in to meet the challenge; she’ll try a new approach if first attempts fall short.
Walensky brought a plaque from her desk in Boston to CDC headquarters in Atlanta. It reads: “Hard things are hard.”
Our stories may be republished online or in print under Creative Commons license CC BY-NC-ND 4.0. We ask that you edit only for style or to shorten, provide proper attribution and link to our web site. Please see our republishing guidelines for use of photos and graphics.